The challenges in therapeutic targeting of the RAF-MEK-ERK signalling pathway

Add to your list(s) Download to your calendar using vCal

• Dr Simon Cook, Babraham Institute
• Thursday 20 February 2020, 09:30-10:30
• Clinical School Lecture Theatre 2.

If you have a question about this talk, please contact Louisa Bellis.

The ERK1 /2 signalling pathway is de-regulated in a variety of cancers due to mutations in RAS (especially KRAS ), BRAF and MEK . This has led to the development of a variety of protein kinase inhibitors that target BRAF , MEK or ERK . Indeed, BRAF and MEK inhibitors are now approved for treatment of melanomas harbouring BRAFV600E /K mutations. This talk will highlight some of the challenges that these kinase inhibitors face – especially intrinsic and acquired resistance – as well as some solutions.

This talk is part of the Cancer Research UK Cambridge Centre Lectures in Cancer Biology and Medicine series.

This talk is included in these lists:

• All Talks (aka the CURE list)
• Biology
• CCC talks for website
• CRUK CI Seminars
• Cancer Research UK Cambridge Centre Lectures in Cancer Biology and Medicine
• Clinical School Lecture Theatre 2
• Featured lists
• Hanchen DaDaDash
• Life Sciences
• Life Sciences
• ME Seminar
• Seminars
• cancer
• cri
• my_list
• ndk22's list
• other talks
• se393's list
• sfm36

Note that ex-directory lists are not shown.